Skip to main content
Fig. 2 | Cell Communication and Signaling

Fig. 2

From: Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

Fig. 2

Characterization of NP-Nrf2_siRNA-CPs. (a) Calibration curve of CP in water, (b) Scanning Electron microscopy image of NP-Nrf2_siRNA-CPs, (ca) CL-Nrf2_siRNA-CPs chemical structure based on Fourier Transform Infrared spectroscopy analysis, (cb) FTIR results of RTX-CL-Nrf2_siRNA-CPs (d) Agarose gel electrophoresis of NP-Nrf2_siRNA-CPs confirming serum stability (lane 1: naked Nrf2 siRNA, 2: 4 h, 3: 6 h, 4: 8 h, 5: 10 h, 6: 12 h, 7: 14 h, 8: 16 h, 9: 18 h), (e) UV spectrophotometer analysis demonstrating in vitro release profile of NP-Nrf2_siRNA-CPs in neutral (PH = 7.2) and acidic (PH = 6) environments

Back to article page